▁tropical ▁dise ases ▁that ▁are ▁primarily ▁found ▁in ▁developing ▁nations . ▁Or phan ▁drug ▁status ▁granted ▁by ▁the ▁European ▁Commission ▁gives ▁market ing ▁exclus ivity ▁in ▁the ▁EU ▁for ▁ 1 0 ▁years ▁after ▁appro val . ▁The ▁EU ' s ▁legisl ation ▁is ▁admin ister ed ▁by ▁the ▁Committee ▁on ▁Or phan ▁Medic inal ▁Product s ▁of ▁the ▁European ▁Medic ines ▁Agency ▁( EMA ). ▁ ▁In ▁late ▁ 2 0 0 7 ▁the ▁F DA ▁and ▁E MA ▁agreed ▁to ▁use ▁a ▁common ▁application ▁process ▁for ▁both ▁ag encies ▁to ▁make ▁it ▁easier ▁for ▁manufact ur ers ▁to ▁apply ▁for ▁or phan ▁drug ▁status ▁but , ▁while ▁continu ing ▁two ▁separate ▁appro val ▁processes . ▁ ▁Other ▁countries ▁Legisl ation ▁has ▁been ▁implemented ▁by ▁Japan , ▁Singapore , ▁and ▁Australia ▁that ▁offers ▁subs id ies ▁and ▁other ▁in cent ives ▁to ▁encou rage ▁the ▁development ▁of ▁dru gs ▁that ▁treat ▁or phan ▁dise ases . ▁ ▁Num bers ▁of ▁new ▁dru gs ▁Under ▁the ▁O DA ▁and ▁EU ▁legisl ation , ▁many ▁or phan ▁dru gs ▁have ▁been ▁developed , ▁including ▁dru gs ▁to ▁treat ▁gli oma , ▁multiple ▁my el oma , ▁c yst ic ▁fib ros is , ▁phen yl ket on uria , ▁s nake ▁ven om ▁poison ing , ▁and ▁id iop ath ic ▁th rom b oc yt open ic ▁pur p ura . ▁ ▁The ▁Ph arma ce ut ical ▁Executive ▁op ines , ▁that ▁the ▁" O DA ▁is ▁nearly ▁univers ally ▁acknowled ged